Trial Protocol: Using genotype to tailor prescribing of nicotine replacement therapy: a randomised controlled trial assessing impact of communication upon adherence.
BACKGROUND: The behavioural impact of pharmacogenomics is untested; informing smokers of genetic test results for responsiveness to smoking cessation medication may increase adherence to this medication. The objective of this trial is to estimate the impact upon adherence to nicotine replacement the...
Main Authors: | Marteau, T, Munafò, MR, Aveyard, P, Hill, C, Whitwell, S, Willis, T, Crockett, R, Hollands, G, Johnstone, E, Wright, A, Prevost, A, Armstrong, D, Sutton, S, Kinmonth, A |
---|---|
Format: | Journal article |
Language: | English |
Published: |
BioMed Central
2010
|
Similar Items
-
Trial Protocol: Using genotype to tailor prescribing of nicotine replacement therapy: a randomised controlled trial assessing impact of communication upon adherence
by: Prevost A Toby, et al.
Published: (2010-11-01) -
Effect on adherence to nicotine replacement therapy of informing smokers their dose is determined by their genotype: a randomised controlled trial.
by: Marteau, T, et al.
Published: (2012) -
Factors influencing the impact of pharmacogenomic prescribing on adherence to nicotine replacement therapy: A qualitative study of participants from a randomized controlled trial
by: Wright, A, et al.
Published: (2018) -
Effect on adherence to nicotine replacement therapy of informing smokers their dose is determined by their genotype: a randomised controlled trial.
by: Theresa M Marteau, et al.
Published: (2012-01-01) -
Trial Protocol: Communicating DNA-based risk assessments for Crohn's disease: a randomised controlled trial assessing impact upon stopping smoking
by: Armstrong David, et al.
Published: (2011-01-01)